BSPOTPE Fluorescence Assay for High-Throughput mAb Aggregation Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening monoclonal antibody aggregation, such as size-exclusion chromatography, are slow and inefficient, taking minutes per sample, making it challenging to screen hundreds of antibodies during lead optimization.
Innovation Solution
A high-throughput fluorescence-based assay using the dye disodium 3,3′-{[(E)-1,2-diphenyl-1,2-ethenediyl]bis(4,1-phenyleneoxy)}di(1-propanesulfonate) (BSPOTPE) to rapidly estimate aggregation in monoclonal antibodies, completing analysis in seconds per sample.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If size-exclusion chromatography is used to analyze monoclonal antibody aggregation, then measurement precision is improved, but productivity deteriorates due to long analysis time of 5-30 minutes per sample
Solution Approach 1:
The patent replaces the mechanical separation system of size-exclusion chromatography with a fluorescence-based optical detection system. The BSPOTPE dye binds to aggregated antibodies and emits fluorescence signals that can be rapidly detected, eliminating the need for slow chromatographic separation while maintaining aggregation detection capability.
Solution Approach 2:
The patent introduces BSPOTPE dye as an intermediary substance that specifically binds to aggregated monoclonal antibodies. This dye acts as a mediator that converts the physical state of aggregation into a measurable fluorescence signal, enabling rapid indirect detection without requiring direct separation or imaging of aggregates.
2Productivity
If fluorescence-based assay with BSPOTPE dye is used, then productivity is improved with analysis time ≤10 seconds per sample, but measurement precision may deteriorate compared to chromatography
Solution Approach 1:
The patent changes the detection parameter from physical separation (chromatography retention time) to optical property (fluorescence intensity). By measuring fluorescence signal strength rather than separation behavior, the method achieves rapid high-throughput screening while maintaining correlation with aggregation levels through calibrated fluorescence intensity measurements.
3Productivity
If rapid screening of hundreds of monoclonal antibodies is performed, then productivity is improved, but loss of time is reduced only marginally when using conventional methods
Solution Approach 1:
The patent performs preliminary action by pre-incubating samples with BSPOTPE dye before rapid fluorescence measurement. This pre-binding step ensures that when samples are introduced to the detection system, the aggregation state is already captured in the fluorescence signal, enabling immediate readout without waiting for separation or processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay significantly reduces analysis time to ≤10 seconds per sample, providing rapid and accurate estimation of monoclonal antibody aggregation with superior sensitivity and specificity, complementing existing chromatography-based workflows.
Implementation Method 1
the added dye increases in fluorescence in linear proportion to the mAb's aggregation content
Data Source
AI summary
The disclosure teaches a high-throughput, fluorescence-based assay for rapid, semi-quantitative estimation of high-molecular weight aggregation in mAb samples. The method rapidly estimates mAb aggregation.